major depressive disorder

Showing NaN - NaN of 113

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

MDD Trial in United States (REL-1017)

Recruiting
  • Major Depressive Disorder
  • Saraland, Alabama
  • +102 more
Jan 18, 2023

MDD Trial in Atlanta (Ketamine, Placebo)

Recruiting
  • Major Depressive Disorder
  • Atlanta, Georgia
    Emory University
Dec 20, 2022

MDD Trial in United States (SAGE-217, Placebo)

Completed
  • Major Depressive Disorder
  • Rogers, Arkansas
  • +52 more
Nov 22, 2022

MDD, Insomnia Trial in United States (SAGE-217, Placebo)

Terminated
  • Major Depressive Disorder
  • Insomnia
  • Little Rock, Arkansas
  • +27 more
Oct 13, 2022

MDD, Treatment Resistant Depression, Depression Trial in United States (AXS-05)

Completed
  • Major Depressive Disorder
  • +2 more
  • AXS-05 (dextromethorphan and bupropion) oral tablets
  • Phoenix, Arizona
  • +50 more
Sep 16, 2022

MDD Trial in Australia, United States (10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114)

Completed
  • Major Depressive Disorder
  • 10 mg PRAX-114
  • +4 more
  • Lafayette, California
  • +23 more
Aug 18, 2022

MDD Trial in Australia, United States (PRAX-114, Placebo)

Completed
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +30 more
Jul 20, 2022

Anhedonia, MDD Trial in Puerto Rico, United States (Placebo, NBI-1065846)

Recruiting
  • Anhedonia
  • Major Depressive Disorder
  • Birmingham, Alabama
  • +11 more
Jun 27, 2022

MDD Trial in United States (SP-624, Placebo)

Active, not recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +38 more
May 13, 2022

MDD Trial in United States (REL-1017, Placebo)

Recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +57 more
May 9, 2022

MDD, Overweight, Inflammation Trial in Atlanta, Boston (Placebo, EPA 1 g/day, EPA 2 g/day)

Completed
  • Major Depressive Disorder
  • +2 more
  • Placebo
  • +3 more
  • Atlanta, Georgia
  • +1 more
Apr 4, 2022

MDD Trial in United States (Lumateperone, Placebo)

Recruiting
  • Major Depressive Disorder
  • Little Rock, Arkansas
  • +16 more
Apr 7, 2022

MDD Trial in Worldwide (Lumateperone)

Enrolling by invitation
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +44 more
Apr 7, 2022

MDD Trial in Canada, United States (PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone)

Completed
  • Major Depressive Disorder
  • PNB01 fixed dose combination of pipamperone and citalopram
  • +2 more
  • Glendale, California
  • +30 more
Mar 14, 2022

MDD Trial in United States (BTRX-335140, Placebo)

Active, not recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +37 more
Mar 11, 2022

MDD Trial in United States (Levomilnacipran ER, Fluoxetine, Placebo)

Completed
  • Major Depressive Disorder
  • Levomilnacipran ER
  • +2 more
  • Little Rock, Arkansas
  • +50 more
Mar 1, 2022

Bipolar Depression, MDD Trial in Worldwide (Lumateperone, Placebos)

Recruiting
  • Bipolar Depression
  • Major Depressive Disorder
  • Garden Grove, California
  • +41 more
Feb 28, 2022

MDD Trial in Atlanta, New York, Dallas (ALTO-300 PO Tablet)

Recruiting
  • Major Depressive Disorder
  • ALTO-300 PO Tablet
  • Atlanta, Georgia
  • +2 more
Feb 3, 2022

Post Traumatic Stress Disorder, MDD Trial in Atlanta (Mindfulness-Based Cognitive Therapy)

Recruiting
  • Post Traumatic Stress Disorder
  • Major Depressive Disorder
  • Mindfulness-Based Cognitive Therapy
  • Atlanta, Georgia
    Grady Health System
Nov 8, 2021

MDD Trial in United States (SAGE-217, Placebo)

Terminated
  • Major Depressive Disorder
  • Bentonville, Arkansas
  • +45 more
Oct 15, 2021

Depression, MDD Trial in United States (AXS-05, Placebo)

Completed
  • Depression
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +42 more
Sep 22, 2021

Depressive Disorder, Depression, Depressive Disorder, Major Trial in United States (Synchronized Transcranial Magnetic

Completed
  • Depressive Disorder
  • +4 more
  • Synchronized Transcranial Magnetic Stimulation (sTMS)
  • Sham Stimulation
  • La Jolla, California
  • +13 more
Aug 9, 2021

MDD Trial in Worldwide (SPD489 (Lisdexamfetamine dimesylate) + Antidepressant)

Terminated
  • Major Depressive Disorder
  • SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
  • Birmingham, Alabama
  • +211 more
Jun 9, 2021

MDD Trial in United States (Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + )

Completed
  • Major Depressive Disorder
  • Antidepressant + SPD489 (lisdexamfetamine dimesylate)
  • Antidepressant + placebo
  • Newport Beach, California
  • +14 more
Jun 8, 2021

MDD Trial in United States (CP-601,927, Placebo)

Terminated
  • Major Depressive Disorder
  • Little Rock, Arkansas
  • +57 more
Apr 7, 2021